US05465P1012 - Common Stock
AXONICS INC
NASDAQ:AXNX (9/24/2024, 8:00:01 PM)
After market: 69.28 +0.02 (+0.03%)69.26
+0.25 (+0.36%)
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 797 full-time employees. The company went IPO on 2018-10-31. The firm has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. The company engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
AXONICS INC
26 Technology Drive
Irvine CALIFORNIA 92618
P: 19493966322
CEO: Raymond W. Cohen
Employees: 797
Website: https://www.axonics.com/
Explore robotics stocks with the potential to grow investors' wealth as the industry expands across various sectors.
AXNX stock results show that Axonics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Axonics (NASDAQ:AXNX) just reported results for the first quarter of 2024.Axoni...
Here you can normally see the latest stock twits on AXNX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: